Organic Process Research & Development
Article
(d, J = 7.0 Hz, 1H), 6.61 (d, J = 7.1 Hz, 1H). Other data were
consistent with those previously reported.12
salt 3 (4.23 kg, 12.9 mol) was charged, followed by 4 M HCl
(12 L). The batch was then heated to 45 °C for 40 h and 50 °C
for a further 8 h and then cooled to 12 °C overnight. Water (15
L) was added over 1.5 h, and the slurry was aged for 30 min
and then filtered. The cake was washed with 1:1 THF/water (2
× 11.8 L). Drying overnight at 45−50 °C under vacuum
afforded the product 1 as a yellow solid (3.73 kg, 86.7 wt %,
89.4 A%). Crude 1 (3.73 kg, 6.95 mol) was slurried in THF (28
kg) and heated to 52 °C. 1,1′-Carbonyldiimidazole (1.13 kg,
6.95 mol) was charged portionwise over 10 min, and the batch
was heated to 55 °C for 1 h and then 58 °C for 3 h. The slurry
was cooled to 15 °C, and aqueous ammonium hydroxide (1.67
kg of a 16 M solution, 29.66 mol) was added over 15 min,
keeping T < 25 °C. The batch was then heated to 45 °C, and
water (44.5 kg) was charged over 1.5 h to crystallize the
product, which was filtered and washed with 3:1 water/THF
(14.8 L). Drying at 50 °C under vacuum gave the product 1·
THF solvate as a yellow solid (3.38 kg, 98.7 A%, 96.1 wt %) in
74% yield.
3-Nitropyridine-2,4-diamine (17). 2,4-Dichloro-3-nitropyr-
idine (16) (6.4 kg, 33.6 mol) was charged into the vessel, and
an aqueous ammonia solution (35.5 kg, 25%) was added. The
mixture was heated at 91 °C for 7 h while an internal pressure
of 4090 mbar was maintained. The reaction mixture was cooled
to ambient temperature and filtered under vacuum. The solid
was washed with water (2 × 15 L) and dried in the vacuum
oven at 55 °C to yield 17 (4.83 kg, 101 wt %, 99 A%) in 94%
yield. 1H NMR (400 MHz, DMSO-d6): δ 8.00 (s, 2H), 7.76 (s,
2H), 7.57 (d, J = 5.7 Hz, 1H), 6.08 (d, J = 5.7 Hz, 1H). Other
data were consistent with those previously reported.13
3-Nitro-N4-[(trifluoromethyl)pyridin-2-yl]pyridine-2,4-dia-
mine (19). 2-Chloro-5-(trifluoromethyl)pyridine (18) (3.02 kg,
16.6 mol) was melted in a water bath at 50 °C, and DMPU (2
L) was added. 3-Nitropyridine-2,4-diamine (17) (2.35 kg, 15.1
mol) and DMPU (11.6 L) were charged into a 50 L vessel,
followed by the solution of 18. The reaction was heated to 55
°C. NaOt-Bu (4.16 kg, 43.3 mol) was added in 0.32 kg portions
(addition time 5 h). The batch was quenched by the addition of
ethanol (14 L). Acetic acid (2.55 L in 25 L of water) was then
added, maintaining an internal temperature of 65 °C (addition
time 1 h). The reaction was stirred for 30 min and then cooled
to room temperature. The slurry was filtered, and the filter cake
was washed with ethanol/water (24 L). The wet cake was dried
in a vacuum oven at 50 °C to give the title compound 19 as a
5-Trifluoromethyl-6-(8-{[5-trifluoromethyl)pyridine-2-yl]-
amino}pyrido{2,3-b]pyrazin-3-yl)nicotinamide Monohydrate
(1·H2O). The THF solvate of 1 (3.73 kg, 96.1 wt %) was
slurried in an ethanol/water mixture (10.7 kg of ethanol, 53.9
kg of water) and heated to 47 °C for 17 h. The resultant slurry
was cooled to 23 °C and filtered, washing with an ethanol/
water mix (1.4 kg of ethanol, 13.5 kg of water). Drying for 18 h
at 40 °C under vacuum afforded 1·H2O as a yellow solid (3.19
1
1
kg, 99.5 A%, 100 wt %) in 95% yield. H NMR (400 MHz,
yellow solid (3.5 kg, 90.5 LCWP, 97 LCAP) in 70% yield. H
DMF-d6): δ 10.85 (br s, 1H), 9.76 (d, J = 1 Hz, 1H), 9.64 (s,
1H), 9.31 (d, J = 5 Hz, 1H), 9.26 (d, J = 5 Hz, 1H), 9.13 (d, J =
1 Hz, 1H), 9.02 (d, J = 2 Hz, 1H), 8.92 (br s, 1H), 8.39 (dd, J =
2 Hz, 9 Hz, 1H), 8.20 (br s, 1H), 8.18 (d, J = 9 Hz, 1H). 13C
NMR (400 MHz, DMF-d6): δ 165.1, 157.8, 156.5, 155.2, 154.0,
151.8, 149.8, 145.2 (q, J = 4 Hz), 144.8, 143.5, 135.5 (q, J = 5
Hz), 135.2 (q, J = 3 Hz), 130.5, 129.5, 125.3 (q, J = 34 Hz),
124.8 (q, J = 271 Hz), 123.8 (q, J = 274 Hz), 119.1 (q, J = 33
Hz), 114.4, 110.3. HRMS (EI): calcd 480.1008 for (M + H),
found 480.0996. Mp: Loss of water with Tmax of 155 °C,
followed by two further events at 232 and 318 °C.
NMR (400 MHz, DMSO-d6): δ 10.47 (s, 1H), 8.60 (s, 1H),
8.09 (dd, J = 2.3, 2.3 Hz, 1H), 8.04 (d, J = 5.6 Hz, 1H), 7.51 (s,
2H), 7.39 (d, J = 5.7 Hz, 1H), 7.31 (d, J = 8.7 Hz, 1H). 13C
NMR (100 MHz, DMSO-d6): δ 155.3, 153.8, 151.9, 145.3,
144.3, 135.84, 119.3, 114.3, 105.2. Anal. Calcd for
C11H8F3N5O2: C, 44.16; H, 2.69; N, 23.41. Found: C, 44.06;
H, 2.63; N, 23.13. Mp 244.6 °C.
N4-[4-(Trifluoromethyl)pyridin-2-yl]pyridine-2,3,4-triamine
Acetate (3·AcOH). 3-Nitro-N4-[(trifluoromethyl)pyridin-2-yl]-
pyridine-2,4-diamine (19) (6.7 kg) was charged into the vessel,
and ethyl acetate (95.5 L) was added. Pd/C (5 wt %, 670 g)
suspended in ethyl acetate (5 L) was added, followed by ethyl
acetate (20.6 L). The mixture was stirred at 28 °C under a
hydrogen pressure of 50 psi for 18 h. The reaction mixture was
filtered, washing the catalyst with ethyl acetate (14.9 L). The
filtrate was transferred to a second vessel, and acetic acid (1.5
L) was added over 30 min. The resulting slurry was stirred at
ambient temperature for 12 h. The slurry was filtered, and the
solid was washed with ethyl acetate (14.9 L). The solid was
dried at 40 °C in a vacuum oven to give 3·AcOH (6.03 kg, 99
wt %, 100 A%) in 91% yield. 1H NMR (400 MHz, DMSO-d6):
δ 8.69 (s, 1 H), 8.42 (s, 1H), 7.83 (dd, J = 2.4, 2.4 Hz, 1H),
7.29 (d, J = 5.5 Hz, 1 H), 6.84 (d, J = 8.8 Hz, 1 H) 6.80 (d, J =
5.5, 1H), 5.51 (bs, 2 H), 1.90 (s, 3H). 13C NMR (100 MHz,
DMSO-d6): δ 172.8, 159.0, 150.3, 145.8, 135.7, 134.9 (m),
130.39, 125.0 (q, J = 269.9 Hz), 121.95, 115.45 (q, J = 32.1
Hz), 110.8−108.2 (m, 2C, two overlapping quartets, J = 26 and
52.1 Hz), 21.73. Anal. Calcd for C13H14F3N5O2: C, 47.42; H,
4.29; N, 21.27. Found: C, 47.47; H, 4.35; N, 20.78. Mp: 183.2
°C.
AUTHOR INFORMATION
Corresponding Authors
■
*Fax: +44 1992 452581. Phone: +44 1992 452179. E-mail:
Notes
The authors declare no competing financial interest.
REFERENCES
■
(1) Szallasi, A.; Cortright, D. N.; Blum, C. A.; Eid, S. R. Nat. Rev.
Drug Discovery 2007, 6, 357.
(2) (a) Westway, S. M. J. Med. Chem. 2007, 50, 2589. (b) Gharat, L.;
Szallasi, A. Drug Dev. Res. 2007, 68, 477.
(3) (a) Hodgetts, K. J.; Blum, C. A.; Caldwell, T.; Bakthavatchalam,
R.; Zheng, X.; Capitosti, S.; Krause, J. E.; Cortright, D.; Crandall, M.;
Murphy, B. A.; Boyce, S. A.; Jones, A. B.; Chenard, B. L. Bioorg. Med.
Chem. Lett. 2010, 20, 4359. (b) 1 was developed in collaboration with
Neurogen Corporation, a Subsidiary of Ligand Pharmaceuticals Inc.,
11119 North Torrey Pines Road, Suite 200, La Jolla, CA 92037, USA.
(4) Rosenmund, K. W.; Struck, E. Chem. Ber. 1916, 52, 1749.
(5) Serratosa, F. Tetrahedron 1961, 16, 185.
5-Trifluoromethyl-6-(8-{[5-(trifluoromethyl)pyridine-2-yl]-
amino}pyrido{2,3-b]pyrazin-3-yl)nicotinamide (1). 6-Dieth-
oxyacetyl-5-trifluoromethylnicotinamide (2) (3.16 kg corrected
for 93 wt %, 9.19 mol) was dissolved in NMP (12 L), and N4-
[5-(trifluoromethyl)pyridin-2-yl]pyridine-2,3,4-triamine acetate
(6) Scheibler, H.; Depner, M. Chem. Ber. 1935, 68, 2154.
(7) Kawasaki, K.; Masubuchi, M.; Morikami, K.; Sogabe, S.; Aoyama,
T.; Ebiike, H.; Niizuma, S.; Hayase, M.; Fujii, T.; Sakota, K.; Shindoh,
1566
dx.doi.org/10.1021/op400304h | Org. Process Res. Dev. 2013, 17, 1561−1567